CORDIS
EU research results

CORDIS

English EN
CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease

CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease

Objective

WHO estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress with conventional treatments is making incremental gains, there remains a need to develop innovative therapeutic approaches. Gene therapy has gained significant momentum, mainly for treatment of rare monogenetic diseases. Marketing authorization for gene therapy products has not impacted diseases such as CVD. Recent, deeper understanding of the molecular/cellular mechanisms of CVD and technology associated with more efficient and safer gene therapy vectors has allowed new opportunities for development of next-generation ATMPs for CVD. CardioReGenix focuses on technological innovations for the treatment of CVD, in particular heart failure and myocardial ischemia. We aim to overcome bottlenecks in gene therapy for CVD by (i) maximizing cardiac-specific gene expression; (ii) maximizing cardiac-specific gene delivery; (iii) reducing adverse immune responses; (iv) optimizing manufacturing for research and clinical-grade ATMPs ; (v) validate new promising targets using in vitro and preclinical models; (vi) undertaking first-in-man studies; (vii) developing and implementing an exploitation and valorization strategy with strong EU SME involvement. CardioReGenix is a high risk/high gain project supported by robust preliminary data and multi-disciplinary consortium harnessing know-how in vector development, GMP manufacturing, preclinical and clinical cardiology, regulation of ATMP and liaising with EMA, business development and clinical translation. CardioReGenix will (i) strengthen Europe's competitive position in gene therapy development for CVD; (ii) improve the prospect of successfully treating patients suffering from CVD by gene therapy and (iii) develop and refine the latest gene therapy platforms that go significantly beyond the state of the art.

Coordinator

VRIJE UNIVERSITEIT BRUSSEL

Address

Pleinlaan 2
1050 Brussel

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 987 859

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 1 564 156

A2F ASSOCIATES LIMITED

United Kingdom

EU Contribution

€ 718 845

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 1 193 622,50

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 1 013 675

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 1 356 501,25

STICHTING VUMC

Netherlands

EU Contribution

€ 1 106 750,75

BATAVIA BIOSCIENCES BV

Netherlands

EU Contribution

€ 776 507,50

FINVECTOR OY

Finland

EU Contribution

€ 1 601 405,75

CARDIOR PHARMACEUTICALS GMBH

Germany

EU Contribution

€ 908 249,50

ASPHALION SL

Spain

EU Contribution

€ 310 035

POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA

Finland

EU Contribution

€ 890 640

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Germany

EU Contribution

€ 1 411 526,25

Project information

Grant agreement ID: 825670

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2023

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 14 839 773,50

  • EU contribution

    € 14 839 773,50

Coordinated by:

VRIJE UNIVERSITEIT BRUSSEL

Belgium